One-Year Safety Analysis of the COMPARE-AMI Trial: Comparison of Intracoronary Injection of CD133⁺ Bone Marrow Stem Cells to Placebo in Patients after Acute Myocardial Infarction and Left Ventricular Dysfunction

Table 3

In-hospital, 4- and 12-month reported adverse events. SVT indicates sustained ventricular tachycardia, ICD implantable cardioverter-defibrillator, BMS bare metal stent DES drug-eluting stent, BM bone marrow, and IC intracoronary.

	In-hospital	4 months	12 months
Mortality (𝑛)	0	0	0
Re-infarct (𝑛)	0	0	0
Stroke (𝑛)	0	0	0
SVT/ICD (𝑛)	0	0	0
Heart failure (𝑛)	2	1	1
Stent thrombosis (𝑛)	0	0	0
In-BMS restenosis/occlusion	0	3	0
In-DES restenosis/occlusion	0	0	0
Bleeding/transfusion (𝑛)	2/0	0/0	0/0
BM harvest related (𝑛)	0	NA	NA
IC Injection related (𝑛)	0	NA	NA